Copyright
©2010 Baishideng.
World J Gastroenterol. Jan 14, 2010; 16(2): 176-183
Published online Jan 14, 2010. doi: 10.3748/wjg.v16.i2.176
Published online Jan 14, 2010. doi: 10.3748/wjg.v16.i2.176
Table 1 Primer sequences for the analysed variants
Gene | SNP | Primers (5’-3’) |
IL23R | rs1004819 | F: GCATTCTAGGACCGTTTTGG |
R: ATCTGGTGGAAATATGTGAAACCTA | ||
IL23R | rs2201841 | F: GGCAAAAGGGAATTGAGAGG |
R: GGCCTATGATTATGCTTTTTCCTG1 | ||
ATG16L1 | rs2241880 | F: CTCTGTCACCATATCAAGCGTGG |
R: TCTAGAAGGACAGGCTATCAACAGATG | ||
CARD15 | rs2066844 | F: GAGCCGCACAACCTTCAGATC |
R: ACTTGAGGTGCCCAACATTCAG | ||
CARD15 | rs2066845 | F: GAGGCCACTCTGGGATTGAG |
R: TAGACTCTGAAGCTTACCTGCGC1 | ||
CARD15 | rs2066847 | F: TGGCTAACTCCTGCAGTCTC |
R: GATCCTCAAAATTCTGCCATTC | ||
IGR2198a_1 | rs11739135 | F: AGACACTGGGACATCATCTGTCTG |
R: GGGCAATTCTATGAGGACATTTAGA | ||
IGR2096a_1 | rs12521868 | F: CAAGATTTCTGCCATAGCCTCCT |
R: GGAGGGTGGTGTAGCCAGAGTAG |
Table 2 Case-control genotypes and allele frequencies of variants in IL23R, ATG16L1, CARD15 and IBD5 n (%)
CD (n = 315) | Controls (n = 314) | OR (95% CI)1 | P | |
IL23R (rs1004189) | ||||
GG | 119 (37.8) | 151 (48.1) | ||
GA | 152 (48.3) | 140 (44.6) | ||
GA+AA | 196 (62.2) | 163 (51.9) | 1.50 (1.09-2.08) | 0.013a |
AA | 44 (14.0) | 23 (7.3) | 2.05 (1.20-3.50) | 0.008a |
RAF | 0.381 | 0.296 | 0.001a | |
IL23R (rs2201841) | ||||
TT | 131 (41.6) | 152 (48.4) | ||
TC | 139 (44.1) | 145 (46.2) | ||
TC+CC | 184 (58.4) | 162 (25.8) | 1.28 (0.93-1.76) | 0.14 |
CC | 45 (14.3) | 17 (5.4) | 2.97 (1.65-5.33) | < 0.001a |
RAF | 0.363 | 0.285 | 0.003a | |
ATG16L1 T300A (rs2241880) | ||||
AA | 56 (17.8) | 72 (22.9) | ||
AG | 151 (47.9) | 163 (51.9) | ||
AG+GG | 259 (82.2) | 242 (77.1) | 1.45 (0.98-2.17) | 0.06 |
GG | 108 (34.3) | 79 (25.2) | 1.69 (1.19-2.41) | 0.004a |
RAF | 0.583 | 0.511 | 0.011a | |
CARD15 R702W (rs2066844) | ||||
CC | 275 (87.3) | 294 (93.6) | ||
CT | 38 (12.1) | 18 (5.7) | ||
CT+TT | 40 (12.7) | 20 (6.4) | 2.13 (1.19-3.80) | 0.011a |
TT | 2 (0.6) | 2 (0.6) | 0.62 (0.06-6.98) | 0.70 |
RAF | 0.067 | 0.035 | 0.011a | |
CARD15 G908R (rs2066845) | ||||
GG | 299 (94.9) | 305 (97.1) | ||
GC | 16 (5.1) | 9 (2.9) | ||
GC+CC | 16 (5.1) | 9 (2.9) | 1.65 (0.71-3.86) | 0.24 |
CC | 0 (0.0) | 0 (0.0) | NC | NC |
RAF | 0.025 | 0.014 | 0.17 | |
CARD15 L1007fs (rs2066847) | ||||
- - | 264 (83.8) | 291 (92.7) | ||
- insC | 42 (13.3) | 23 (7.3) | ||
- insC+insC insC | 51 (16.2) | 23 (7.3) | 2.57 (1.51-4.36) | < 0.001a |
insC insC | 9 (2.9) | 0 (0.0) | NC | NC |
RAF | 0.095 | 0.037 | < 0.001a | |
CARD15 status2 | ||||
- | 220 (69.8) | 262 (83.4) | ||
+ | 95 (30.2) | 52 (16.6) | 2.17 (1.46-3.21) | < 0.001a |
IGR2198a_1 (rs11739135) | ||||
GG | 91 (28.9) | 120 (38.2) | ||
GC | 160 (50.8) | 144 (45.9) | ||
GC+CC | 251 (79.7) | 194 (61.8) | 1.54 (1.10-2.15) | 0.013a |
CC | 64 (20.3) | 50 (15.9) | 1.32 (0.87-1.99) | 0.19 |
RAF | 0.457 | 0.389 | 0.014a | |
IGR2096a_1 (rs12521868) | ||||
GG | 94 (29.8) | 120 (38.2) | ||
GT | 149 (47.3) | 142 (45.2) | ||
GT+TT | 296 (94.0) | 262 (83.4) | 1.44 (1.03-2.02) | 0.034a |
TT | 72 (22.9) | 52 (16.6) | 1.45 (0.97-2.17) | 0.07 |
RAF | 0.465 | 0.392 | 0.009a |
Table 3 Pairwise analysis of interactions of CARD15, IBD5 (IGR2198a_1), ATG16L1 and IL23R to risk of CD
Model | OR (95% CI) | P |
IL23R rs1004189 * ATG16L1 | 1.51 (0.73-3.11) | 0.26 |
IL23R rs2201841 * ATG16L1 | 1.01 (0.29-3.57) | 0.99 |
IL23R rs1004189 * CARD15 status1 | 1.20 (0.54-2.67) | 0.65 |
IL23R rs2201841 * CARD15 status | 1.57 (0.30-8.31) | 0.60 |
IL23R rs1004189 * IGR2198a_1 | 1.30 (0.71-2.36) | 0.40 |
IL23R rs2201841 * IGR2198a_1 | 0.46 (0.12-1.75) | 0.25 |
ATG16L1 * CARD15 status | 1.49 (0.59-3.80) | 0.40 |
ATG16L1 * IGR2198a_1 | 0.95 (0.45-2.00) | 0.89 |
CARD15 status * IGR2198a_1 | 0.75 (0.33-1.71) | 0.49 |
Table 4 Genotype-specific CD odds ratios1 (with 95% CI) for combinations of variants in IL23R, ATG16L1 and CARD15
CARD15 R702W | CARD15 G908R | CARD15 L1007fs | CARD15 status | ATG16L1 | ||||||
CC | CT+TT | GG | GC+CC | - - | - insC+insC insC | - | + | AA+AG | GG | |
IL23R rs1004189 | ||||||||||
GG | 1 | 2.35 (1.03-5.34)a | 1 | 1.55 (0.46-5.21) | 1 | 2.85 (1.28-6.35)a | 1 | 2.100 (1.17-3.76)a | 1 | 1.16 (0.68-1.99) |
GA+AA | 1.56 (1.12-2.19)a | 3.18 (1.45-6.97)a | 1.51 (1.09-2.09)a | 3.23 (0.99-10.57) | 1.57 (1.12-2.20)a | 3.40 (1.69-6.82)a | 1.50 (1.04-2.16)a | 3.33 (1.96-5.67)a | 1.34 (0.92-1.95) | 2.51 (1.55-4.08)a |
IL23R rs2201841 | ||||||||||
TT+TC | 1 | 2.25 (1.26-4.03)a | 1 | 1.49 (0.62-3.59) | 1 | 2.43 (1.42-4.18)a | 1 | 2.12 (1.42-3.16)a | 1 | 1.48 (1.03-2.14)a |
CC | 3.04 (1.67-5.57)a | 4.75 (0.53-42.81) | 2.69 (1.49-4.86)a | NC | 2.89 (1.57-5.32)a | 8.52 (1.04-69.74)a | 2.70 (1.42-5.15)a | 9.15 (2.05-40.74)a | 2.67 (1.31-5.44)a | 4.68 (1.72-12.78)a |
ATG16L1 | ||||||||||
AA+AG | 1 | 2.20 (1.14-4.26)a | 1 | 1.44 (0.56-3.72) | 1 | 2.37 (1.29-4.34)a | 1 | 2.12 (1.35-3.31)a | - | - |
GG | 1.57 (1.09-2.25)a | 3.18 (1.11-9.08)a | 1.51 (1.06-2.14)a | 6.91 (0.83-57.92) | 1.54 (1.07-2.22)a | 4.27 (1.54-11.79)a | 1.54 (1.04-2.27)a | 3.82 (1.86-7.86)a | - | - |
Table 5 Genotype-specific CD odds ratios1 (with 95% CI) for combinations of variants in IBD5, IL23R and ATG16L1
IL23R rs1004189 | IL23R rs2201841 | ATG16L1 | ||||
GG | GA+AA | TT+TC | CC | AA+AG | GG | |
IGR2198a_1 | ||||||
GG | 1 | 1.43 (0.80-2.53) | 1 | 4.83 (1.52-15.37)a | 1 | 1.71 (0.94-3.09) |
GC+CC | 1.45 (0.84-2.48) | 2.44 (1.43-4.15)a | 1.58 (1.11-2.24)a | 3.66 (1.81-7.41)a | 1.60 (1.07-2.38)a | 2.38 (1.46-3.87)a |
IGR2096a_1 | ||||||
GG | 1 | 1.55 (0.88-2.73) | 1 | 4.03 (1.39-11.62)a | 1 | 1.63 (0.91-2.92) |
GT+TT | 1.49 (0.87-2.56) | 2.41 (1.42-4.09)a | 1.50 (1.06-2.13)a | 3.71 (1.80-7.67)a | 1.50 (1.01-2.24)a | 2.32 (1.42-3.79)a |
Table 6 Genotype-specific CD odds ratios1 (with 95% CI) for combinations of variants in IBD5 and CARD15
CARD15 R702W | CARD15 G908R | CARD15 L1007fs | CARD15 status | |||||
CC | CT+TT | GG | GC+CC | - - | - insC+insC insC | - | + | |
IGR2198a_1 | ||||||||
GG | 1 | 3.17 (1.15-8.69)a | 1 | 1.79 (0.39-8.22) | 1 | 3.04 (1.30-7.14)a | 1 | 2.65 (1.36-5.17)a |
GC+CC | 1.60 (1.13-2.27)a | 2.819 (1.39-5.72)a | 1.52 (1.08-2.13)a | 2.69 (0.97-7.45) | 1.61 (1.13-2.31)a | 3.58 (1.80-7.16)a | 1.63 (1.11-2.39)a | 3.19 (1.90-5.37)a |
IGR2096a_1 | ||||||||
GG | 1 | 3.07 (1.20-7.86)a | 1 | 2.19 (0.51-9.41) | 1 | 2.43 (1.06-5.59)a | 1 | 2.46 (1.29-4.69)a |
GT+TT | 1.55 (1.09-2.20)a | 2.75 (1.32-5.70)a | 1.47 (1.05-2.06)a | 2.41 (0.86-6.77) | 1.48 (1.03-2.11)a | 3.74 (1.85-7.54)a | 1.54 (1.05-2.26)a | 3.18 (1.87-5.39)a |
- Citation: Csöngei V, Járomi L, Sáfrány E, Sipeky C, Magyari L, Faragó B, Bene J, Polgár N, Lakner L, Sarlós P, Varga M, Melegh B. Interaction of the major inflammatory bowel disease susceptibility alleles in Crohn’s disease patients. World J Gastroenterol 2010; 16(2): 176-183
- URL: https://www.wjgnet.com/1007-9327/full/v16/i2/176.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i2.176